Gavin K Thomas

Mr. Gavin K Thomas


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Journal of Biomechanics
Verified
Journal Article
Open access
VJVenus Joumaa
Venus Joumaa
FSFaizan Syed
Faizan Syed
JHJason J. Howard
Jason J. Howard
GTGavin K Thomas
Gavin K Thomas
LOLatif Omerkhil
Latif Omerkhil
Walter HerzogWalter Herzog
Walter Herzog
The aim of this study was to gain insight into the origins of muscle weakness in children with cerebral palsy (CP) by investigating active force in single muscle fibres isolated from the adductor longus (AL) of children with CP. Single skinned muscle fibres (n = 43, from 11 children with CP) were isolated and tested for their maximal active stress, instantaneous stiffness, and the ratio of active stress to stiffness at a sarcomere length (SL) of 2.4 µm, and passive stress at SLs of 2.4, 2.6, 2.8, 3.0, 3.2, and 3.4 µm. The muscle biopsies were tested for their total myofibrillar protein content using a BCA assay, and myosin heavy chain, actin, titin and nebulin content using gel electrophoresis. Muscle biopsies from the vastus lateralis of healthy adults (HA; n = 19 fibres from 4 subjects) were used for comparison. The maximal active stress and the instantaneous stiffness, expressed as active elastic modulus, were lower in the CP fibres compared to the HA fibres (79 ± 4 vs. 170 ± 11 kPa, and 5479 ± 381 vs. 8943 ± 402 kPa, respectively). The maximal active stress to stiffness ratio was not different between CP and HA fibres (0.016 ± 0.001 vs. 0.020 ± 0.002). Actin, titin and nebulin content was reduced in the CP compared to the HA samples. Passive stress was also reduced in the CP fibres at SLs of 2.8, 3.0, 3.2 and 3.6 µm. These results suggest that the contractile ability of muscles from children with CP is compromised at the fibre level and this is likely the result of a decrease in sarcomeric proteins such as actin, titin and nebulin.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GTGavin K Thomas
Gavin K Thomas
ESEric E. Smith
Eric E. Smith
ZIZahinoor Ismail
Zahinoor Ismail
JKJulia G Kirkham
Julia G Kirkham
PRPamela Roach
Pamela Roach
DSDallas Seitz
Dallas Seitz
Background: Potential disease modifying therapies (DMT) for Alzheimer’s disease (AD) may become available in Canada although it is unclear what percentage of people presenting to tertiary care memory programs may require beta‐amyloid testing be eligible for these treatments. We evaluated eligibility for potential DMTs among individuals in the Prospective Registry for Persons with Memory Symptoms (PROMPT) dementia research registry, comprising patients seen in a tertiary care cognitive clinic in Calgary, Alberta, Canada, based on cognitive criteria, medical history, and potential diagnosis of AD on clinical criteria.Method: We analyzed all individuals included in the PROMPT registry from July 2010 to May 2023 who were diagnosed with either mild cognitive impairment (MCI) or possible or probable dementia at their baseline assessment. AD biomarker testing is not routinely available in this clinic. The characteristics of PROMPT participants were then compared to the inclusion criteria used in recent trials of three DMTs. The proportions of individuals in the PROMPT registry who were potentially eligible for DMTs were then determined.Result: Of the 1,901 individuals in the PROMPT registry, 1,119 were diagnosed with MCI or dementia at their baseline visit (mean age 75 years and 54% male). Among the group with MCI or dementia, 86% (965) were diagnosed with either MCI or AD. Of the individuals diagnosed with MCI or AD, 55‐80% met cognitive test score eligibility for different DMTs at their initial clinic visit. Potential medical contraindications to treatment with DMTs were present in 27% of this sample. Of all individuals referred to the tertiary care cognitive disorders clinic diagnosed with MCI or AD, approximately 40‐58% could potentially be eligible for DMTs based on their initial clinic assessment. Of all individuals in the PROMPT dementia registry, between 20‐29% could potentially be candidates for DMTs pending neuroimaging and biomarker confirmation of eligibility.Conclusion: A high proportion of memory clinic referrals are diagnosed with MCI or AD and are potentially eligible for DMTs and would require beta‐amyloid biomarker testing for eligibility confirmation. This information will help better define resource requirements for implementing AD DMTs should these become available in Canada.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
GTGavin K Thomas
Gavin K Thomas
NFNils D. Forkert
Nils D. Forkert
ESEric E. Smith
Eric E. Smith
GMGeoffrey Messier
Geoffrey Messier
MCMohammad Z I Chowdhury
Mohammad Z I Chowdhury
DSDallas Seitz
Dallas Seitz
Background: Mild cognitive impairment (MCI) and dementia affect a growing proportion of the aging population, placing significant demands on healthcare systems. While administrative health records (AHRs) capture broad healthcare data, their usefulness in identifying MCI and dementia is limited by a lack of expert‐confirmed diagnostic information. The Prospective Registry for Persons with Memory Symptoms (PROMPT) provides specialist‐confirmed diagnoses and detailed clinical information, creating a unique opportunity to validate machine learning (ML) models in real‐world settings. By linking PROMPT's registry data with population‐level AHRs, this study addresses current gaps in early detection and staging of cognitive decline, with implications for both clinical practice and health policy. Method: We analyzed data from 1,901 adults referred to a tertiary memory clinic in Calgary, Canada (2010–2023), with records linked to provincial Administrative Health Records (AHRs). Cognitive status was classified as “no objective impairment” (NOI), mild cognitive impairment (MCI), or dementia through comprehensive multidisciplinary assessments, including neuropsychological testing and specialist evaluations. Predictor variables derived from AHRs encompassed diagnostic codes, medication dispensations, and healthcare utilization patterns. We developed and compared multiple machine learning (ML) algorithms, including logistic regression, random forests, and ensemble methods, against previously established rule‐based approaches from a Canadian study. Model performance was evaluated using the F1 score to balance sensitivity and specificity, along with overall accuracy metrics. Results: Of the 1,901 participants (mean age 73 years, 52% male), 34% ( n = 646) were diagnosed with dementia, 44% ( n = 836) with MCI, 12% ( n = 228) with NOI, and 10% ( n = 191) received an 'uncertain' diagnosis. Initial analyses demonstrated expected patterns in cognitive assessment scores across diagnostic groups, including the Mini‐Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). Complete model performance metrics, including sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), are currently being finalized and will be presented. Conclusion: Forthcoming results will clarify how specialist‐confirmed data from PROMPT can enhance ML‐based classification of MCI and dementia in AHRs. These findings have the potential to improve surveillance of cognitive disorders, inform healthcare resource allocation, and guide earlier interventions. By integrating advanced analytics with validated clinical information, this project could shape future approaches to dementia care in Canada and beyond.